max-40279
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 16, 2019 (NCT04187495)
Timeline
Indications
Mechanism of action
MAP4K1 inhibitor
- Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
FLT3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05425602 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2022 | Maxinovel Pty., Ltd. |
| NCT05369286 | Phase 1 | Apr 11, 2022 | Maxinovel Pty., Ltd., Sun Yat-Sen University |
| NCT05130021 | Phase 2 | Nov 10, 2021 | Maxinovel Pty., Ltd. |
| NCT05061147 | Phase 1/Phase 2 (Phase 2) | Sep 16, 2021 | Maxinovel Pty., Ltd. |
| NCT04183764 | Phase 1 | Nov 28, 2019 | Maxinovel Pty., Ltd. |
| NCT04187495 | Phase 1 | Apr 16, 2019 | Maxinovel Pty., Ltd. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Maxinovel Pty., Ltd. | For profit | 6 | 6 | 2 | 2019 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1